Biotech Showcase™ 2017: ProNAI defects from oligos to DDR as Sierra Oncology

January 26, 2017
Sierra Oncology president and CEO Dr. Nick Glover tells Mike Ward, Informa Pharma Intelligence insight global director of content, how the company is rebranding itself from its former incarnation ProNAI Therapeutics, armed with two in-licensed assets focused on DNA damage repair (DDR) and USD 100 million in the bank.
Previous Article
Inositec CEO on 2017 financing plans
Inositec CEO on 2017 financing plans

Inositec is developing innovative new drugs using its proprietary Inositune technology to adjust the proper...

Next Article
Deciphera CEO on tackling cancer drug resistance
Deciphera CEO on tackling cancer drug resistance

CEO Michael Taylor talks about Deciphera Pharmaceuticals’ cell-signaling technology and explains the compan...